Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | PDE6A | P16499 | 1/20 | 0.37 |
| ▸ | PDE6G | P18545 | 1/20 | 0.37 |
| ▸ | PDE6B | P35913 | 1/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979689 | 0.91 | HSD11B1 (0.54) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL7987890 | 0.91 | HSD11B1 (0.56) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL12671298 | 0.90 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL12671073 | 0.85 | HSD11B1 (0.53) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL12671290 | 0.84 | HSD11B1 (0.54) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL1417957 | 0.84 | HSD11B1 (0.54) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL12671291 | 0.83 | HSD11B1 (0.56) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL7982083 | 0.83 | HSD11B1 (0.51) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL1418244 | 0.83 | HSD11B1 (0.53) | HSD11B1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL7989134 | 0.82 | HSD11B1 (0.46) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885PDE2A 1318/4885PDE6D 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.